- Home
- ORBS vs LAB Comparison
ORBS vs LAB Comparison
Compare ORBS & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORBS | LAB |
|---|---|---|
| Founded | 1966 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 373.9M | 384.1M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | ORBS | LAB |
|---|---|---|
| Price | $1.01 | $0.97 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.35 |
| AVG Volume (30 Days) | ★ 25.3M | 2.4M |
| Earning Date | 04-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.54 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $101,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.74 | $0.92 |
| 52 Week High | $15.96 | $1.72 |
Technical Indicators
Market Signals| Indicator | ORBS | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 46.34 | 34.09 |
| Support Level | $0.74 | $0.92 |
| Resistance Level | $1.29 | $1.41 |
| Average True Range (ATR) | 0.15 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 53.05 | 18.77 |
Price Performance
Historical ComparisonAbout ORBS Eightco Holdings Inc.
Eightco Holdings Inc operates in Forever 8 Inventory Cash Flow Solution. The company is a dynamic technology-focused company committed to driving growth and innovation through strategic acquisitions and management. Forever 8 focuses on purchasing inventory for e-commerce retailers and is part of its Inventory Solution Business.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.